Search

Your search keyword '"Malling, H.-J."' showing total 92 results

Search Constraints

Start Over You searched for: Author "Malling, H.-J." Remove constraint Author: "Malling, H.-J." Search Limiters Full Text Remove constraint Search Limiters: Full Text
92 results on '"Malling, H.-J."'

Search Results

1. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

2. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

3. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

4. 2019 ARIA Care pathways for allergen immunotherapy

5. 2019 ARIA Care pathways for allergen immunotherapy

7. Abstracts from the Food Allergy and Anaphylaxis Meeting 2016

8. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies

9. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

10. Allergy immunotherapy across the life cycle to promote active and healthy ageing

11. Allergy immunotherapy across the life cycle to promote active and healthy ageing: From research to policies

12. Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

13. Allergy immunotherapy across the life cycle to promote active and healthy ageing:from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

14. Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies

15. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper

16. EAACI: a European declaration on immunotherapy. Design the future of allergen specific immunotherapy

17. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: An ARIA-GA2LEN statement

18. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper

19. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy

20. CXC chemokine receptor 4 expression and stromal cell-derived factor-1α-induced chemotaxis in CD4+ T lymphocytes are regulated by interleukin-4 and interleukin-10

21. The current state of recombinant allergens for immunotherapy

22. The T cell response to major grass allergens is regulated and includes IL-10 production in atopic but not in non-atopic subjects

25. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper

26. Grass pollen symptoms interfere with the recollection of birch pollen symptoms - a prospective study of suspected, asymptomatic skin sensitization

27. Safety and tolerability of grass pollen tablets in sublingual immunotherapy--a phase-1 study

28. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets

29. Double blind placebo controlled exposure to molds:exposure system and clinical results

30. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy:A randomized, placebo-controlled, double-blind, double-dummy study

31. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy:a randomized, placebo-controlled, double-blind, double-dummy study

32. Association between an interleukin-13 promoter polymorphism and atopy

33. Retrospective assessment of seasonal allergic symptoms:over-rating but useful

35. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study

36. CXCR3 expression on CD34(+) hemopoietic progenitors induced by granulocyte-macrophage colony-stimulating factor:II. Signaling pathways involved

37. Standardization of food allergen extracts for skin prick test

38. CXCR3 expression and activation of eosinophils:role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma

39. CXC chemokine receptor 3 expression on CD34(+) hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor:chemotaxis and adhesion induced by its ligands, interferon gamma-inducible protein 10 and monokine induced by interferon gamma

40. Histamine and tryptase in nasal lavage fluid after allergen challenge:effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine

41. Histamine and tryptase in nasal lavage fluid following challenge with methacholine and allergen

43. Precise area determination of skin-prick tests:Validation of a scanning device and software for a personal computer

44. CXC chemokine receptor 4 expression and stromal cell‐derived factor‐1α‐induced chemotaxis in CD4+ T lymphocytes are regulated by interleukin‐4 and interleukin‐10.

45. Maxisorp RAST. A sensitive method for detection of antigen-specific human IgE in culture fluids

46. A sensitive and reproducible method for the determination of subnanogram quantities of immunoglobulin E (IgE)

47. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy

48. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies

49. 2019 ARIA Care pathways for allergen immunotherapy

50. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.

Catalog

Books, media, physical & digital resources